Novartis Sues AstraZeneca, Two Others Over Patent
This article is for subscribers only.
Novartis AG’s vaccines unit sued AstraZeneca Plc’s MedImmune subsidiary, Biogen Idec Inc. and Alexion Pharmaceuticals Inc., alleging some drugs they make infringe a 1997 U.S. patent for diagnostic gene sequences.
The complaint, filed Jan. 26 in federal court in Delaware, targets AstraZeneca’s Synagis respiratory treatment; Biogen’s Tysabri for multiple sclerosis; and Alexion’s Soliris, used to treat a life-threatening form of anemia.